Ben Bronstein

Dr. Bronstein has extensive experience as a founder, senior executive, and investor in public and private life sciences companies, including roles as CEO, COO and CMO. Dr. Bronstein founded or held senior management positions at venture-backed firms including BioSurface Technology, Inc. (regenerative medicine; acquired by Genzyme Corp., later Sanofi SA;NASDAQ:SNY), Peptimmune, Inc. (immunotherapeutics; acquired by Genzyme Corp., later Sanofi SA;NASDAQ:SNY)), Vidus Ocular, Inc. (implantable glaucoma treatment devices; acquired by OPKO Health, Inc.; NASDAQ:OPK) and Neuron Systems, Inc. (now Aldeyra Therapeutics, Inc.; NASDAQ:ALDX). Additionally, he served as a Visiting Scholar at the Wyss Institute of Biologically Inspired Engineering at Harvard Medical School. He is a director of Aldeyra Therapeutics and several other life science companies. A board certified pathologist with more than 20 publications, Dr. Bronstein began his professional career on the staff of the Massachusetts General Hospital and on the faculty of Harvard Medical School.